enGene to Host KOL Webinar on October 15, 2026
Business Wire•13/10/2026•08:00 ET
0
Key Highlights
- ➤October 15 webinar will detail surfactant-rinse preclinical data supporting detalimogene development
- ➤LEGEND trial enrolls high-risk, BCG-unresponsive NMIBC patients with CIS in additional cohort
- ➤David J. Cahn and Suzanne B. Merrill will present real-world treatment considerations
- ➤Detalimogene remains investigational non-viral gene therapy for high-risk NMIBC
Community Key Opinion Leaders (KOLs) to present on real-world clinical decision making in high-risk non-muscle invasive bladder cancer (NMIBC)
Additional discussion to focus on preclinical data supporting incorporation of a surfactant bladder rinse plus detalimogene voraplasmid into clinical development
Get started
Create a free account to read the full story.